He called his wife Ann once in the driver's seat to continue the conversation they'd been having over breakfast.

As he made his way towards Mosman in the usual Sydney traffic, a beat-up Toyota Corona was in the queue directly behind him.

At the intersection of Bardwell Rd and Military Rd, the Corona deliberately swerved into Dr Chang's car and so the two cars pulled over on the side of the road.

It was 8am when Phillip Lim and Chiew Seng Liew - the occupants of the Corona - pulled a pistol on Chang.

They wanted money. Lim planned to extort $3 million from a wealthy Asian businessman living in Australia, so he could set up a gambling den or massage parlour. They'd picked Dr Chang after seeing an article about him in a magazine.

Dr Chang pulled out his wallet immediately, but there were numerous witnesses watching on in horror.

Mosman Collectivequotes Chang as yelling out to someone, "call the police, theyve got guns."

He was shot twice - once in the head, once in the stomach. He died at the scene.

Liew was sentenced to a maximum of 26 years in prison for firing the two shots that killed Dr Chang. After 21 years, he was released and deported back to his home country of Malaysia in 2012.

As The Sydney Morning Heraldreported, it was a decision that "devastated" Dr Chang's family.

"I made a mistake," Liew told the Sevennetwork upon his release. "I did the wrong thing and made the family suffer ... You know I want to apologise for the family."

His co-accused Lim was granted parole after serving his minimum 18-year sentence, which expired in 2009.

Hailed as a "medical genius," Dr Chang was celebrated and admired around the world.

While he personallysaved hundreds of lives, he always had his eye on millions - which could be achieved through medical research.

After his death, the Victor Chang Foundation created by Dr Chang in 1984 with the aim of sharing expertise between Australia and Asia through training in the fields of cardiothoracic surgery, heart and lung transplantation and cardiology, continued on with his work.

But his dream was carried forward even further,with the establishment of The Victor Chang Cardiac Research Institute in 1994. It was opened by Princess Dianawho told those gathered, "Dr Chang was no ordinary cardiac surgeon. He was a visionary."

Follow this link:
Dr Victor Chang saved hundreds of lives. 31 years ago today, he was murdered. - Mamamia

Wilmington, Delaware, United States, Transparency Market Research Inc.: Cell line development is an important technology in life sciences. Stable cell lines are used for various applications including monoclonal antibody and recombinant protein productions, gene functional studies, and drug screening

Read Report Overview - https://www.transparencymarketresearch.com/cell-line-development-market.html

Manual screening method is a traditional method used for cell line development. This method is tend to be disadvantageous as it is labor-intensive and time-consuming. Automation in tools used for cell line development is likely to replace manual methods of cell line development.

Cell line development and culturing is being rapidly adopted in areas of biological drug developments for various chronic diseases, regenerative medicines such as stem cells & cell-based therapies, recombinant protein, and other cellular entities for pharmaceuticals, diagnostics, and various other industries.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75773

Key Drivers and Opportunities of Global Cell Line Development Market

Rise in focus on research & development, owing to increase in prevalence of cancer and other chronic diseases is anticipated to drive the market. Several institutes, such as Cancer Research Institute, National Cancer Institute, Advanced Centre for Treatment, Research and Education in Cancer (Cancer Research Centre [ICRC]), and NCI Community Oncology Research Program (NCORP), are engaged in research & development for cancer diagnosis and treatment. Hence, the initiative of government and non-government organizations is likely boost the growth of the market.

Mammalian cell lines are widely used as production tools for various biologic drugs. Technological advancement in cell line development in mammalian cell culturing is likely to fuel the growth of the market. For instance, according to an article published in Pharmaceuticals (Basel), the U.S. Food and Drug Administered approved 15 novel recombinant protein therapeutics from 2005 to 2011 on an average.

Advances in bioinformatics and recombinant technologies have led to development of new cell lines for synthesis or production of essential peptides, enzymes, saccharides, and other molecules which are being used in pharmaceuticals and various other industries.

Request for Analysis of Cell Line Development Market Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=75773

North America to Capture Major Share of Global Cell Line Development Market

North America is expected to account for major share of the global cell line development market due to well-established health care infrastructure and rise in government initiatives. Furthermore, adoption of innovative technologies is likely to augment the market in the region.

The cell line development market in Asia Pacific is expected to grow at a rapid pace during the forecast period, owing to increasing risk of communicable diseases, cancer, and chronic & rare diseases and surge in geriatric population. For instance, according to an article published in BioMed Central Ltd, in 2018, 2.9 million cancer deaths occurred and 4.3 million new cancer cases were recorded in China.

Key Players Operating in Global Cell Line Development Market

The global cell line development market is highly concentrated due to the presence of key players. A large number of manufacturers hold major share in their respective regions. Key players engaged in adopting new strategies are likely to drive the global cell line development market. Key players are developing new, cost-effective biologic products. This is anticipated to augment the market.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=75773

Major players operating in the global cell line development market are:

More Trending Reports by Transparency Market Research

Surgical Retractors Market: Surgical Retractors Market (Product Type: Hand-held Retractors, Self-retaining Retractors, Table-mounted Retractors, and Others; Application: Abdominal Surgeries, Cardiothoracic Surgeries, Orthopedic Surgeries, Obstetric & Gynecological Surgeries, and Others; and End User: Hospitals, Ambulatory Surgical Centers, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Dental Consumables Market: Dental Consumables Market (Product - Dental Implants, Crowns and Bridges, Dental Biomaterials, Orthodontics, Endodontics, Periodontics, Retail Dental Care Essentials, and Dental Consumables) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Vascular Stents Market: Vascular Stents Market (Type: Coronary Artery Stents, Peripheral Vascular Stents, and Neurovascular Stents; Delivery Method: Balloon Expandable Stents and Self-expanding Stents; Material: Cobalt-Chromium Stent, Platinum-Chromium Stent, Nitinol Stent, Stainless Steel Stent, and Bioresorbable Polymer Stent; End User: Hospitals, Cardiac Centers, and Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Monopolar Electrosurgery Market: Monopolar Electrosurgery Market (Product Type - Hand Instruments, Electrosurgical Generator, Return Electrode (Single Use and Re-usable), Accessories (Footswitches and Connectors); Application - General Surgery, Gynecology Surgery, Cardiovascular Surgery, Cosmetic Surgery, Orthopedic Surgery, and Urology Surgery; End User: Hospitals, Ambulatory Surgical Centers, and Specialty Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Vertebroplasty and Kyphoplasty Market: Vertebroplasty and Kyphoplasty Market (Product - Vertebroplasty (Needles, Cement Mixing and Delivery Devices), Kyphoplasty (Needles, Balloons, Cement Mixing and Delivery Devices); End use - Hospitals, Ambulatory Surgery Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Air Bubble Detectors Market: Air Bubble Detectors Market (Product Type: Fixed Detectors and Flexible Detectors; Technology: Ultrasonic Sensors and Capacitive Sensors; Application: Dialysis & Transfusion, Cardiopulmonary Bypass, Infusion & Parenteral Infusion Pumps, Diagnostic Devices, Blood Processing Equipment, and Others; and End User: Hospitals & Healthcare Providers, Diagnostic Laboratories, and Pharmaceuticals & Biotechnology Industries) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Refurbished Medical Equipment Market: Refurbished Medical Equipment Market (Product: Medical Imaging Equipment, Operating Room Equipment, Patient Monitoring Devices, and Others; Application: Cardiology, Respiratory and Gastroenterology, Neonatal Care, Orthopedic, and Others; and End User: Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Medical Laser Systems Market: Medical Laser Systems Market (Product Type: Gas Lasers, Solid-state Lasers, Fiber Lasers, Diode Lasers, Femtosecond Lasers, and Others; Application: Ophthalmology, Cosmetic/Dermatology, Dentistry, Cancer Therapy, Cardiovascular, and Others; and End User: Hospitals, Ambulatory Surgical Centers, and Specialized Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 2030

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

Visit link:
Cell Line Development Market: Increase in Prevalence of Cancer and Other Chronic Diseases to Drive the Market - BioSpace

Get PDF Sample on this Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&Raj

The global exosome therapeutics market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to the exosome therapeutics market.

For instance,

Collaboration, joint ventures, and other strategies by the market player are enhancing the company market in the global exosome therapeutics market, which also provides the benefit for an organization to improve their offering for treatment products.

Get TOC Details of this Report @ https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&Raj

Some of the major companies influencing this market include:

Some of the major companies providing the global exosome therapeutics market are Stem Cells Group, Exosome Sciences, AEGLE Therapeutics, Capricor Therapeutics, Avalon Globocare Corp, CODIAK, Kimera Labs, Stem Cell Medicine Ltd, Exopharm, Jazz Pharmaceuticals, Inc., evox THERAPEUTICS, ReNeuron Group plc, and EV Therapeutics, among others.

Market Segmentation:-

The global exosome therapeutics market is segmented on the basis of type, source, therapy, transporting capacity, application, route of administration, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

The global exosome therapeutics market is categorized into seven notable segments which are based on type, source, therapy, transporting capacity, application, route of administration, and end user.

Regions Covered in Artificial Intelligence in Genomics 2022 Global Market Report:

Browse Full In Depth Research Report @ https://www.databridgemarketresearch.com/reports/global-exosome-therapeutic-market?Raj

Key questions answered in the report include:who are the key market players in the this Market?Which are the major regions for dissimilar trades that are expected to eyewitness astonishing growth for the this Market?What are the regional growth trends and the leading revenue-generating regions for the this Market?What will be the market size and the growth rate by the end of the forecast period?What are the key this Market trends impacting the growth of the market?What are the major Product Types of this Market?What are the major applications of this Market?

Related Reports:-

https://www.databridgemarketresearch.com/reports/global-vivo-imaging-market

https://www.databridgemarketresearch.com/reports/global-computer-assisted-coding-market

https://www.databridgemarketresearch.com/reports/global-diagnostic-catheter-market

https://www.databridgemarketresearch.com/reports/global-active-implantable-medical-devices-market

https://www.databridgemarketresearch.com/reports/global-swine-respiratory-diseases-treatment-market

https://www.databridgemarketresearch.com/reports/global-microplate-systems-market

https://www.databridgemarketresearch.com/reports/global-patient-access-solutions-market

https://www.databridgemarketresearch.com/reports/global-probiotics-market

About us:

An absolute way to forecast what future holds is to comprehend the trend today!

data bridge market researchset forth itself as an unconventional and neoteric market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in pune.

Data bridge market research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and habridge market research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact us:

Data bridge market research

Us: +1 888 387 2818

Uk: +44 208 089 1725

Hong kong: +852 8192 7475

Email: corporatesales@databridgemarketresearch.com

Here is the original post:
Exosome Therapeutics Market Research Report Size, Share, New Trends and Opportunity, Competitive Analysis and Future Forecast Designer Women -...

Homology Medicines, Inc.

AAVHSC16 Biodistribution Properties in Preclinical Models Demonstrated Potential for Systemic Delivery of Genetic Medicines to Brain, Heart and Muscle

BEDFORD, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the peer-reviewed publication of data showing that AAVHSC16, one of the capsids in its family of 15 naturally occurring AAVHSCs, demonstrated low levels of tropism to the liver while maintaining robust distribution to the central nervous system (CNS) and peripheral organs following a single I.V. administration in preclinical models. The Company believes that its unique properties, with high levels of tropism to the brain, heart and muscle, and no elevations in liver enzymes, could make AAVHSC16 an attractive capsid for new disease indications with Homologys genetic medicines platform.

Our ongoing efforts to fully characterize our family of 15 naturally occurring AAVHSCs as it relates to biodistribution, tissue tropism and the role different features of the capsids play, continues to reveal their unique profiles that allow us to best select capsids for different diseases, said Albert Seymour, Ph.D., President and Chief Scientific Officer of Homology Medicines. In the case of AAVHSC16 with its ability to reach key tissues without targeting the liver in preclinical models, we can potentially expand into additional disease areas where we want to deliver to the CNS, cardiac tissue, or muscle while avoiding exposure in the liver. By continuing to publish our discoveries about the unique structure and function of our AAVHSCs, we believe we can contribute to the fields greater understanding and development of AAV-based therapies that will ultimately benefit more patients.

Homologys AAVHSC capsids differ from each other by one to four amino acids, resulting in differences in biodistribution and transduction efficiencies. As described in the manuscript, AAVHSC16 has two unique amino acids, 501I and 706C, in addition to 505R that is shared across six AAVHSC serotypes. A series of experiments demonstrated that these amino acids contribute to AAVHSC16s unique properties, which include significantly reduced liver tropism compared to other AAVs, no liver enzyme elevations, and high tissue tropism to the CNS and other peripheral organs. Specifically, these data demonstrated:

Story continues

Naturally Occurring Variations in AAVHSC16 Alter Cellular Binding Affinity In Vitro

AAVHSC16 does not share the galactose (a type of glycan) binding feature of other AAVHSCs and Clade F AAVs in vitro. AAVHSC16 did not show improved binding or a difference in number of vector genomes (vgs) or eGFP expression in cells with terminally exposed galactose, while other AAVHSCs tested did.

The combination of the unique naturally occurring amino acids at positions 501I and 505R in AAVHSC16 were shown to contribute to reduced galactose-binding.

AAVHSC16 Has Significantly Reduced Liver Transduction in In Vivo and In Vitro Models, with High Tropism to other Tissues Following a Single I.V. Administration

In murine models, a single I.V. administration of AAVHSC16 showed significantly lower levels of liver tropism compared to AAVHSC15 and AAV9. The liver was the only organ with significant differences as AAVHSC16 demonstrated high levels of tropism to all other organs evaluated, including the brain, heart and muscle; these levels were comparable to those observed with AAVHSC15 and AAV9.

Further, in non-human primates (NHPs), a single I.V. administration of AAVHSC16 resulted in substantially lower liver expression than AAVHSC15, while maintaining high and equivalent levels of transduction in the brain, heart and muscle.

In vitro data also showed that AAVHSC16 led to lower expression in primary human liver cells compared to other tested wild type AAVHSCs and AAV9, and it revealed that AAVHSC16s 706 residue was the main contributor to this outcome.

AAVHSC16 Did Not Lead to Elevations in Liver Function Tests

In NHPs, a single I.V. administration of AAVHSC16 at 7E+13 and 1E+14 vg/kg doses did not result in elevated ALT (alanine transaminase) or AST (aspartate transferase) levels at any timepoint post-dose compared to baseline levels or vehicle-treated controls.

Comparing AAVHSC16 liver transduction and ALT and AST levels to AAV9 and other AAVHSCs further suggested that the lack of ALT and AST elevations with AAVHSC16 is associated with its lower liver tropism.

The publication, Natural Variations in AAVHSC16 Significantly Reduce Liver Tropism and Maintain Broad Distribution to Periphery and CNS, was peer-reviewed and published in the journal Molecular Therapy - Methods & Clinical Development. For more information, please click here or http://www.homologymedicines.com/publications.

About Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Companys clinical programs include HMI-102, an investigational gene therapy for adults with phenylketonuria (PKU); HMI-103, a gene editing candidate for PKU; and HMI-203, an investigational gene therapy for Hunter syndrome. Additional programs focus on metachromatic leukodystrophy (MLD), paroxysmal nocturnal hemoglobinuria (PNH) and other diseases. Homologys proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus (AAVHSCs) vectors to precisely and efficiently deliver genetic medicines in vivo through a gene therapy or nuclease-free gene editing modality, as well as to deliver one-time gene therapy to produce antibodies throughout the body through the GTx-mAb platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit http://www.homologymedicines.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the potential to expand the application of AAVHSC16 to other disease areas; our expectations surrounding the potential, safety, and efficacy of our product candidates; the potential of our gene therapy and gene editing platforms; and our position as a leader in the development of genetic medicines. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies and clinical trials, and on general economic conditions; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property; risks associated with international operations, such as political and economic instability, including in light of the conflict between Russia and Ukraine; and significant costs incurred as a result of operating as a public company. These and other important factors discussed under the caption Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, and our other filings with the Securities and Exchange Commission (SEC) could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Company Contacts:Theresa McNeelyChief Communications Officer and Patient Advocatetmcneely@homologymedicines.com781-301-7277

Media Contact:Cara Mayfield Vice President, Patient Advocacy and Corporate Communications cmayfield@homologymedicines.com 781-691-3510

Here is the original post:
Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and...

Daix (France), Long Island City (New York, United States), July 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical needs, today announced the screening in the United States of America of the first patient in its LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D 1. Over 30 sites located in France, United Kingdom, Belgium, Netherlands and United States have already been qualified to participate in this clinical trial. Topline results are expected to be published in the second half of 2023.

Here is the original post:
Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with...

NX-2127 advanced to Phase 1b in CLL based on promising data in Phase 1a clinical trial

The rest is here:
Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update

SAN DIEGO and GAINESVILLE, Ga., July 07, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the addition of new employees to fill open roles throughout the organization.

Read the original:
Societal CDMO Reports Inducement Grants for New Staff

OXFORD, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enright, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 in New York, July 11 to 12. Mr. Enright will also host one on one meetings with investors at the conference.

View original post here:
Vaccitech to Present at the William Blair Biotech Focus Conference 2022

BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/.

Visit link:
Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant...

Read the original here:
Nicox: 2022 Extraordinary Shareholder Meeting

ADELAIDE, Australia, July 08, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Dr. Errol De Souza, Executive Chairman of Bionomics, will participate in a panel on “Unmet Needs and Novel Therapies in Neuropsychiatry” at the William Blair Biotech Focus Conference taking place virtually and in-person in New York on July 12-13, 2022.

More:
Bionomics to Participate in William Blair’s Biotech Focus Conference 2022

Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis

Read the original here:
Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program

TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 08, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced that it has received final approval from The Nasdaq Capital Market LLC (“Nasdaq”) to list its common shares (the “Common Shares”) on Nasdaq. The Company’s Common Shares will begin trading on Friday, July 8th, 2022, under the symbol “PMN”.

Excerpt from:
ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”

WATERTOWN, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Leigh Morgan to its Board of Directors. Ms. Morgan joins Kymera’s Board as a senior executive accomplished in scaling global, profitable, high-performing organizations.

See the article here:
Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan

Treatment Approved for Smallpox, Monkeypox, Cowpox, and Vaccinia Complications Treatment Approved for Smallpox, Monkeypox, Cowpox, and Vaccinia Complications

Original post:
SIGA Technologies Receives Approval from UK for Tecovirimat

ROCKVILLE, Md., July 08, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that total preliminary unaudited revenue for the second quarter of 2022 was approximately $1.0 million, up from $0.8 million in the second quarter of 2021. Cash as of June 30, 2022 was approximately $16.6 million.

Go here to see the original:
OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update

YAVNE, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced an oral presentation at the Advanced Wound Care Summit taking place on July 13-14, 2022 in Boston, MA.

Follow this link:
MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13

ILUVIEN receives approval and pricing for non-infectious uveitis affecting the posterior segment indication in July; launch to follow ILUVIEN receives approval and pricing for non-infectious uveitis affecting the posterior segment indication in July; launch to follow

Read the original post:
Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy

- Adverum to present new best-corrected visual acuity (BCVA) data from the OPTIC Trial of ADVM-022 (ixoberogene soroparvovec) in wet AMD

See original here:
Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

PRINCETON, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be participating in a virtual panel discussion presented by Maxim Group LLC and hosted by M-Vest. Full details on the panel are as follows:

See the rest here:
Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel